CL2015001419A1 - Compuesto 6-((s)-1-{1-[5-(2-hidroxi-etoxi)-piridin-2-il]-1h-pirazol-3-il}-etil)-3h-1,3-benzotiazol-2-ona, antagonista del receptor ampa dependiente de tarp-gamma 8; composicion farmaceutica que lo comprende; metodo para tratar convulsiones epilepticas y dolor. - Google Patents

Compuesto 6-((s)-1-{1-[5-(2-hidroxi-etoxi)-piridin-2-il]-1h-pirazol-3-il}-etil)-3h-1,3-benzotiazol-2-ona, antagonista del receptor ampa dependiente de tarp-gamma 8; composicion farmaceutica que lo comprende; metodo para tratar convulsiones epilepticas y dolor.

Info

Publication number
CL2015001419A1
CL2015001419A1 CL2015001419A CL2015001419A CL2015001419A1 CL 2015001419 A1 CL2015001419 A1 CL 2015001419A1 CL 2015001419 A CL2015001419 A CL 2015001419A CL 2015001419 A CL2015001419 A CL 2015001419A CL 2015001419 A1 CL2015001419 A1 CL 2015001419A1
Authority
CL
Chile
Prior art keywords
tarp
pyrazol
benzothiazole
pyridin
ethoxy
Prior art date
Application number
CL2015001419A
Other languages
English (en)
Spanish (es)
Inventor
Jon Kevin Reel
Warren Jaye Porter
Jeffrey Michael Witkin
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2015001419A1 publication Critical patent/CL2015001419A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2015001419A 2012-11-27 2015-05-26 Compuesto 6-((s)-1-{1-[5-(2-hidroxi-etoxi)-piridin-2-il]-1h-pirazol-3-il}-etil)-3h-1,3-benzotiazol-2-ona, antagonista del receptor ampa dependiente de tarp-gamma 8; composicion farmaceutica que lo comprende; metodo para tratar convulsiones epilepticas y dolor. CL2015001419A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261730273P 2012-11-27 2012-11-27

Publications (1)

Publication Number Publication Date
CL2015001419A1 true CL2015001419A1 (es) 2015-10-02

Family

ID=49753484

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001419A CL2015001419A1 (es) 2012-11-27 2015-05-26 Compuesto 6-((s)-1-{1-[5-(2-hidroxi-etoxi)-piridin-2-il]-1h-pirazol-3-il}-etil)-3h-1,3-benzotiazol-2-ona, antagonista del receptor ampa dependiente de tarp-gamma 8; composicion farmaceutica que lo comprende; metodo para tratar convulsiones epilepticas y dolor.

Country Status (35)

Country Link
US (1) US8765960B2 (enExample)
EP (1) EP2925754B1 (enExample)
JP (1) JP6246227B2 (enExample)
KR (1) KR101693133B1 (enExample)
CN (1) CN104797578B (enExample)
AP (1) AP2015008489A0 (enExample)
AR (1) AR093527A1 (enExample)
AU (1) AU2013352594B2 (enExample)
BR (1) BR112015011200A2 (enExample)
CA (1) CA2889243C (enExample)
CL (1) CL2015001419A1 (enExample)
CR (1) CR20150267A (enExample)
CY (1) CY1118657T1 (enExample)
DK (1) DK2925754T3 (enExample)
DO (1) DOP2015000113A (enExample)
EA (1) EA026686B1 (enExample)
ES (1) ES2618260T3 (enExample)
HR (1) HRP20170274T1 (enExample)
HU (1) HUE033447T2 (enExample)
IL (1) IL238831B (enExample)
JO (1) JO3225B1 (enExample)
MA (1) MA38126B1 (enExample)
MX (1) MX356478B (enExample)
MY (1) MY177721A (enExample)
PE (1) PE20151728A1 (enExample)
PH (1) PH12015501154B1 (enExample)
PL (1) PL2925754T3 (enExample)
PT (1) PT2925754T (enExample)
SG (1) SG11201504164VA (enExample)
SI (1) SI2925754T1 (enExample)
TN (1) TN2015000200A1 (enExample)
TW (2) TW201825484A (enExample)
UA (1) UA114345C2 (enExample)
WO (1) WO2014085153A1 (enExample)
ZA (1) ZA201503733B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201609719A (zh) * 2014-05-28 2016-03-16 美國禮來大藥廠 作為TARP-γ8依賴性AMPA受體拮抗劑之6-經取代-3H-1,3-苯并噻唑-2-酮化合物
HRP20210403T1 (hr) 2015-04-29 2021-10-29 Janssen Pharmaceutica Nv Azabenzimidazoli i njihova uporaba kao modulatora ampa receptora
AU2016255431B2 (en) 2015-04-29 2020-05-07 Janssen Pharmaceutica Nv Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators
ES2767707T3 (es) 2015-04-29 2020-06-18 Janssen Pharmaceutica Nv Compuestos de indolona y su uso como moduladores de receptor AMPA
WO2016176449A1 (en) * 2015-04-29 2016-11-03 Janssen Pharmaceutica Nv Benzimidazolone and benzothiazolone compounds and their use as ampa receptor modulators
JP6953527B2 (ja) * 2016-10-26 2021-10-27 ヤンセン ファーマシューティカ エヌ.ベー. 縮合二環ピリジン化合物、及びampa受容体調節因子としてのそれらの使用
RU2650523C1 (ru) 2017-07-24 2018-04-16 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Производное пиридоксина для лечения эпилепсии
RU2703286C1 (ru) * 2019-06-18 2019-10-16 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Соли (5-гидрокси-3,4-бис(гидроксиметил)-6-метилпиридин-2-ил)метансульфокислоты и способ их получения

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY132385A (en) * 1995-08-31 2007-10-31 Novartis Ag 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives
JP2000281676A (ja) * 1999-01-25 2000-10-10 Yamanouchi Pharmaceut Co Ltd Ampa拮抗化合物の新規製造法
PT1300396E (pt) * 2000-06-12 2009-04-20 Eisai R&D Man Co Ltd Compostos de 1,2-di-hidropiridina, processos para a sua preparação e sua utilização
US8995993B2 (en) * 2000-10-11 2015-03-31 Gogo Llc System for managing mobile internet protocol addresses in an airborne wireless cellular network
CN101072775A (zh) * 2004-12-17 2007-11-14 伊莱利利公司 新的mch受体拮抗剂
WO2007076161A2 (en) 2005-12-27 2007-07-05 Myriad Genetics, Inc Compounds with therapeutic activity
TW200817385A (en) * 2006-07-04 2008-04-16 Organon Nv Heterocyclic derivatives
JP2012505198A (ja) * 2008-10-08 2012-03-01 ファイザー・インク Cns障害を治療する際にampa調節剤として使用するためのテトラヒドロフラニルスルホンアミド
HUE025013T2 (hu) * 2009-01-12 2016-04-28 Pfizer Ltd Szulfonamid-származékok
EP2576544A4 (en) * 2010-06-01 2013-09-11 Angion Biomedica Corp INHIBITORS OF CYTOCHROMES P450 AND USES THEREOF
WO2012137982A2 (en) * 2011-04-05 2012-10-11 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
TW201609719A (zh) 2014-05-28 2016-03-16 美國禮來大藥廠 作為TARP-γ8依賴性AMPA受體拮抗劑之6-經取代-3H-1,3-苯并噻唑-2-酮化合物

Also Published As

Publication number Publication date
AP2015008489A0 (en) 2015-05-31
MX2015006697A (es) 2015-08-05
CY1118657T1 (el) 2017-07-12
MY177721A (en) 2020-09-23
JO3225B1 (ar) 2018-03-08
AU2013352594A1 (en) 2015-06-04
AU2013352594B2 (en) 2016-02-18
CR20150267A (es) 2015-09-16
DOP2015000113A (es) 2015-06-15
TW201434834A (zh) 2014-09-16
WO2014085153A8 (en) 2014-07-31
US8765960B2 (en) 2014-07-01
PE20151728A1 (es) 2015-12-02
KR101693133B1 (ko) 2017-01-04
HK1209116A1 (en) 2016-03-24
CA2889243C (en) 2017-06-13
SG11201504164VA (en) 2015-07-30
MA38126A1 (fr) 2017-03-31
WO2014085153A1 (en) 2014-06-05
PL2925754T3 (pl) 2017-07-31
TN2015000200A1 (en) 2016-10-03
IL238831B (en) 2018-08-30
US20140148441A1 (en) 2014-05-29
KR20150070401A (ko) 2015-06-24
JP2016501219A (ja) 2016-01-18
EA026686B1 (ru) 2017-05-31
PH12015501154B1 (en) 2018-05-30
CN104797578A (zh) 2015-07-22
DK2925754T3 (en) 2017-02-20
CA2889243A1 (en) 2014-06-05
MA38126B1 (fr) 2017-11-30
ES2618260T3 (es) 2017-06-21
HUE033447T2 (en) 2017-11-28
TW201825484A (zh) 2018-07-16
PH12015501154A1 (en) 2015-08-10
AR093527A1 (es) 2015-06-10
EP2925754B1 (en) 2016-12-28
IL238831A0 (en) 2015-06-30
BR112015011200A2 (pt) 2017-07-11
TWI618705B (zh) 2018-03-21
EP2925754A1 (en) 2015-10-07
SI2925754T1 (sl) 2017-02-28
HRP20170274T1 (hr) 2017-04-07
CN104797578B (zh) 2016-11-23
PT2925754T (pt) 2017-02-27
MX356478B (es) 2018-05-30
EA201590823A1 (ru) 2015-08-31
UA114345C2 (uk) 2017-05-25
JP6246227B2 (ja) 2017-12-13
ZA201503733B (en) 2017-09-27

Similar Documents

Publication Publication Date Title
CL2015001785A1 (es) Compuestos derivados de heterociclos nitrogenados, moduladores de quinasas; metodo de preparacion; compuesto iintermediario; composicion farmaceutica; y un metodo para tratar un sujeto que posee una enferemedad o condicion como cancer, aml, tumores estromales gastrointestinales o mastocitosis.
JOP20130313B1 (ar) عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
CL2015001168A1 (es) Compuestos derivados de 5-amino-1h-pirazol-4-carboxamida sustituidos, inhibidores de la tirosina-quinasa de bruton (bkt); composicion farmaceutica; metodo para inhibir la bkt; y metodo para tratar enfermedades autoinmunes, inflamatorias y cancer seleccionado de un trastorno proliferativo de celula b seleccionado de linfomas.
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
EP2545058A4 (en) HETEROCYCLIC HEMMER OF HISTAMINE RECEPTORS FOR DISEASE TREATMENT
DK2976074T3 (da) Antagonister af cannabinoid-receptoren CB1 til anvendelse ved behandling af sygdomme associeret med neuronale dendritiske anormaliteter
UY34730A (es) Formulaciones farmacéuticas que comprenden antagonistas de ccr3
CL2012002506A1 (es) Compuestos derivados de heterociclos sustituidos, inhibidores de la enzima pde10; composiciones farmacéuticas que comprenden dichos compuestos; y un método para tratar desórdenes neurológicos en un animal de sangre caliente, tal como esquizofrenia.
DK2773633T3 (da) Heterocykliske forbindelser, medikamenter indeholdende forbindelserne, anvendelse deraf og fremgangsmåder til fremstilling deraf.
BRPI1008727A2 (pt) derivados de azol substituídos, composição farmacêutica contendo os derivados, e método para o tratamento de doença de parkinson usando os mesmos
AP2015008489A0 (en) 6-((S)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1H-pyrazol-3-yl}-ethyl)-3H-1,3-benzothiazol-2-one asa tarp-gamma 8 dependent ampa receptor antagonist
PL3069720T3 (pl) Kompozycja farmaceutyczna zawierająca pochodne glutarimidu i jej zastosowanie w leczeniu chorób eozynofilowych
GB201415655D0 (en) System, method, and interfaces for work product management
PT3044206T (pt) (3z,5s)-5-(hidroximetil)-1-[(2¿-metil-1,1¿-bifenil-4-il)carbonil)pirrolidin-3-ona o-metiloxima como oxitocina/vasopressina via recetores antagonistas para o tratamento de parto prematuro
BRPI0907916A2 (pt) Heterociclos espirociclos, medicamentos contendo esses compostos, e processos para preparar os mesmos
MX2015007051A (es) Diazol lactamas.
CL2015001516A1 (es) Compuestos derivados de piridopirazinas sustituidas, inhibidores de syk; composicion farmaceutica; metodo para tratar una enfermedad inflamatoria, alergias, enfermedad autoinmune, enfermedad proliferativa celular, entre otras.
WO2014100735A3 (en) Diazole amides
EP2883914A4 (en) BIOLOGICAL ASPHALT, BIOLOGICAL ASPHALT COMPOUND AND METHOD OF MANUFACTURING THEREOF
BR112017017317A2 (pt) Ácido (2s,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-4- (etoxioxalilamino)-2-hidroximetil-2-metilpentanóico como inibidor de neprilisina
MX2016005174A (es) Composiciones para uso en la prevencion y el tratamiento de enfermedades neurodegenerativas y dolor.
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
CL2015000890A1 (es) Compuestos derivados de etinilo como moduladores de la actividad del receptor mglur5; proceso de obtencion; composicion farmaceutica que lo contiene; uso en el tratamiento de ansiedad, dolor, depresion, enfermedad de parkinson, entre otras.
IL236437A (en) Acrylamide compounds as histamine h3 receptor ligands, process for preparation, medicinal preparations containing them and their uses
EP2835424A4 (en) DNA-CONTROL MIR-140 EXPRESSION AND MEDICINE SCREENING METHOD WITH THIS DNA